Specific immunotherapy with vaccinia oncolysates

Summary A live vaccinia virus-augmented tumor cell vaccine (vaccinia oncolysate) has been used as a specific active immune mechanism stimulator against certain advanced human cancers. This preliminary trial, in which the same dose of vaccinia oncolysate was used in 29 patients, showed the vaccine to be safe, non-toxic, and potentially effective. This study was designed as a toxicity/feasibility trial at a single vaccine dose. There was no effort to look at other dose levels. The heterogeneity of this early tumor group only reflects the type of patient available to the study during the early phase of vaccine testing. Randomized prospective trials have begun to make future analysis easier.